Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 June 2021 | Story Lunga Luthuli | Photo Lunga Luthuli
South Campus: Social Responsibility Project team with Free State Department of Health nurses during the lunch of the campus’ COVID-19 pop-up vaccination site.

On Monday 27 September 2021, the University of the Free State, Provincial Department of Health and Department of Education launched a pop-up vaccination site at the South Campus bringing much-needed services closer to communities in the fight to end the COVID-19 pandemic.

Thandeka Mosholi, Head of Social Responsibility, Enterprise and Community Engagement, South Campus says, “We are next to the Mangaung community and bringing these services we encourage not only UFS staff and students but the surrounding communities to vaccinate for COVID-19. The institution and stakeholders are saying it is everyone’s responsibility for their health.”

She says, “If vaccination is recommended and we are told that it is safe, we encourage everyone including the youth to preserve our health and vaccinate.”

Representing the Department of Health, Papi Mokhele, Professional Pharmacist, says, “The initiative is aimed at reaching out to as many people to be vaccinated.”

He says, “At the moment the facility administers only the Pfizer vaccination and, as recommended by the National Government, we want to reach herd immunity – about 70% of the population – so that businesses, sporting facilities and many others can open and get our life back to normal.”

Other facilities the Department of Health has recently opened include the SABC Hoffman Square, Majakathata Taxi Rank, MUCCPP Health Centre in Phelindaba, Puma Garage in Bergman and Mangaung Outdoor Centre.

On partnering with the UFS, Mokhele says, “The COVID-19 vaccines have been put through clinical processes and quality assurance tests. They have also been approved by the South African Medicine Control Council and we call on the UFS community, especially students, to register and vaccinate.”

Coretha van den Heever, Teacher Trainer in the Social Responsibility Project, was recently vaccinated for the pandemic and says, “Let us protect ourselves and other people and not be the spreaders of the virus.”

She says, “People must make use of the facility; the UFS and government have brought the solution closer so that communities will not have to spend a lot of money travelling to get help.”

The vaccination centre will operate from Monday to Friday from 9:00 to 16:00.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept